Evidence mapPaperPMID 40697404Full record

ReviewCanadian respiratory journal2025

Current Understanding of Pulmonary Fibrosis: Pathogenesis, Diagnosis, and Therapeutic Approaches.

Dinglu Cui, Xiangguo Che, Rongxian An, Lei Li, Xinying Cui, Long Jiang, Jingchun Jin

Abstract readReview
In one paragraph

Review in Canadian respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dinglu CuiDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.ORCID 0009-0005-1616-440X
Xiangguo CheDepartment of Biochemistry and Cell Biology, Korea Mouse Phenotyping Center, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.ORCID 0000-0002-7272-1806
Rongxian AnDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.
Lei LiDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.
Xinying CuiDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.
Long JiangDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.
Jingchun JinDepartment of Rheumatology, Yanbian University Hospital, Yanji, China.ORCID 0000-0002-3985-2513

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a terminal-stage lung change in interstitial lung disease. It is characterized by proliferation of fibroblasts and deposition of a large amount of extracellular matrix, accompanied by inflammatory damage and structural destruction, caused by various reasons. The prognosis of PF is poor, and the average survival time after diagnosis is 2.5-3.5 years. The pathogenesis of PF is not yet fully understood. Its main mechanisms are diverse and include damage to alveolar epithelial cells, aggregation and activation of inflammatory cells and chemokines, proliferation of fibroblasts, transformation of myofibroblasts, production and deposition of large amounts of collagen, autophagy, epithelial-mesenchymal transition (EMT), mitochondrial quality-control disorders, microRNA, and circular RNA. The diagnosis of PF is mainly based on the comprehensive evaluation of clinical manifestations, imaging characteristics, and histopathological examination. Medical and family history to determine all potential causes of PF. For PF of unknown etiology, one can refer to the Official Clinical Practice Guideline of idiopathic pulmonary fibrosis (IPF) for definitive diagnosis. In terms of treatment, modern medications such as pirfenidone and nintedanib can inhibit the progression of PF to some extent and improve lung function. However, there is no drug that can significantly improve PF, except for lung transplantation. In addition, many patients are forced to stop taking medication due to adverse reactions in clinical practice. Therefore, to better control the progression of disease, some new drugs have been developed based on the pathogenesis of PF. However, there is still controversy over their efficacy and widespread clinical application in PF, and the evidence is limited. The results of in vitro and in vivo experiments, as well as randomized clinical trials, indicate that traditional Chinese medicine (TCM) can improve PF by intervening in multiple pathways and targets. This study combines the pathogenesis and diagnosis of PF, focusing on the intervention mechanism and targets of TCM in the treatment of PF, so as to provide more options for clinical treatment and provide scientific basis for a new approach to better management of PF.

Indexed as

Idiopathic Pulmonary FibrosisPulmonary FibrosisEpithelial-Mesenchymal TransitionHumansIndolesLung TransplantationMicroRNAsPyridonesIndolesMicroRNAsnintedanibpirfenidonePyridonesdiagnosispathogenesispulmonary fibrosisTCM prescriptiontraditional Chinese medicinetreatment

Identifiers

PMID40697404
PMCPMC12283196

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.